Leonard C Rogers1, Jing Zhou1,2, Adriana Baker1,3, Charles R Schutt1, Prashanta K Panda1, Brian A Van Tine4,5,6. 1. Division of Medical Oncology, Washington University in St. Louis, St. Louis, Missouri, 63110, USA. 2. The First Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi, China. 3. University of Nevada, Las Vegas, Las Vegas, NV, 89154, USA. 4. Division of Medical Oncology, Washington University in St. Louis, St. Louis, Missouri, 63110, USA. bvantine@wustl.edu. 5. Division of Pediatric Hematology/Oncology, St. Louis Children's Hospital, St. Louis, MO, 63110, USA. bvantine@wustl.edu. 6. Siteman Cancer Center, St. Louis, MO, 63110, USA. bvantine@wustl.edu.
Abstract
BACKGROUND: Many cancers silence the metabolic enzyme argininosuccinate synthetase 1 (ASS1), the rate-limiting enzyme for arginine biosynthesis within the urea cycle. Consequently, ASS1-negative cells are susceptible to depletion of extracellular arginine by PEGylated arginine deiminase (ADI-PEG20), an agent currently being developed in clinical trials. As the primary mechanism of resistance to arginine depletion is re-expression of ASS1, we sought a tool to understand the temporal emergence of the resistance phenotype at the single-cell level. METHODS: A real-time, single-cell florescence biosensor was developed to monitor arginine-dependent protein translation. The versatile, protein-based sensor provides temporal information about the metabolic adaptation of cells, as it is able to quantify and track individual cells over time. RESULTS: Every ASS1-deficient cell analyzed was found to respond to arginine deprivation by decreased expression of the sensor, indicating an absence of resistance in the naïve cell population. However, the temporal recovery and emergence of resistance varied widely amongst cells, suggesting a heterogeneous metabolic response. The sensor also enabled determination of a minimal arginine concentration required for its optimal translation. CONCLUSIONS: The translation-dependent sensor developed here is able to accurately track the development of resistance in ASS1-deficient cells treated with ADI-PEG20. Its ability to track single cells over time allowed the determination that resistance is not present in the naïve population, as well as elucidating the heterogeneity of the timing and extent of resistance. This tool represents a useful advance in the study of arginine deprivation, while its design has potential to be adapted to other amino acids.
BACKGROUND: Many cancers silence the metabolic enzyme argininosuccinate synthetase 1 (ASS1), the rate-limiting enzyme for arginine biosynthesis within the urea cycle. Consequently, ASS1-negative cells are susceptible to depletion of extracellular arginine by PEGylated arginine deiminase (ADI-PEG20), an agent currently being developed in clinical trials. As the primary mechanism of resistance to arginine depletion is re-expression of ASS1, we sought a tool to understand the temporal emergence of the resistance phenotype at the single-cell level. METHODS: A real-time, single-cell florescence biosensor was developed to monitor arginine-dependent protein translation. The versatile, protein-based sensor provides temporal information about the metabolic adaptation of cells, as it is able to quantify and track individual cells over time. RESULTS: Every ASS1-deficient cell analyzed was found to respond to arginine deprivation by decreased expression of the sensor, indicating an absence of resistance in the naïve cell population. However, the temporal recovery and emergence of resistance varied widely amongst cells, suggesting a heterogeneous metabolic response. The sensor also enabled determination of a minimal arginine concentration required for its optimal translation. CONCLUSIONS: The translation-dependent sensor developed here is able to accurately track the development of resistance in ASS1-deficient cells treated with ADI-PEG20. Its ability to track single cells over time allowed the determination that resistance is not present in the naïve population, as well as elucidating the heterogeneity of the timing and extent of resistance. This tool represents a useful advance in the study of arginine deprivation, while its design has potential to be adapted to other amino acids.
Authors: G K Abou-Alfa; S Qin; B-Y Ryoo; S-N Lu; C-J Yen; Y-H Feng; H Y Lim; F Izzo; M Colombo; D Sarker; L Bolondi; G Vaccaro; W P Harris; Z Chen; R A Hubner; T Meyer; W Sun; J J Harding; E M Hollywood; J Ma; P J Wan; M Ly; J Bomalaski; A Johnston; C-C Lin; Y Chao; L-T Chen Journal: Ann Oncol Date: 2018-06-01 Impact factor: 32.976
Authors: Konstantinos Tzelepis; Hiroko Koike-Yusa; Etienne De Braekeleer; Yilong Li; Emmanouil Metzakopian; Oliver M Dovey; Annalisa Mupo; Vera Grinkevich; Meng Li; Milena Mazan; Malgorzata Gozdecka; Shuhei Ohnishi; Jonathan Cooper; Miten Patel; Thomas McKerrell; Bin Chen; Ana Filipa Domingues; Paolo Gallipoli; Sarah Teichmann; Hannes Ponstingl; Ultan McDermott; Julio Saez-Rodriguez; Brian J P Huntly; Francesco Iorio; Cristina Pina; George S Vassiliou; Kosuke Yusa Journal: Cell Rep Date: 2016-10-18 Impact factor: 9.423
Authors: Gregory R Bean; Jeff C Kremer; Bethany C Prudner; Aaron D Schenone; Juo-Chin Yao; Matthew B Schultze; David Y Chen; Munir R Tanas; Douglas R Adkins; John Bomalaski; Brian P Rubin; Loren S Michel; Brian A Van Tine Journal: Cell Death Dis Date: 2016-10-13 Impact factor: 8.469
Authors: Jeff Charles Kremer; Bethany Cheree Prudner; Sara Elaine Stubbs Lange; Gregory Richard Bean; Matthew Bailey Schultze; Caitlyn Brook Brashears; Megan DeAnna Radyk; Nathan Redlich; Shin-Cheng Tzeng; Kenjiro Kami; Laura Shelton; Aixiao Li; Zack Morgan; John Stephen Bomalaski; Takashi Tsukamoto; Jon McConathy; Loren Scott Michel; Jason Matthew Held; Brian Andrew Van Tine Journal: Cell Rep Date: 2017-01-24 Impact factor: 9.423